Company Overview of Cubist Pharmaceuticals LLC
Cubist Pharmaceuticals LLC, a biopharmaceutical company, is engaged in the research, development, and commercialization of pharmaceutical products for medical needs in the acute care environment in the United States. It offers CUBICIN (daptomycin for injection), a once-daily, bactericidal, intravenous antibiotic with activity against methicillin-resistant Staphylococcus aureus; DIFICID for the treatment of clostridium difficile-associated diarrhea (CDAD); and ENTEREG (alvimopan), an oral peripherally-acting mu opioid receptor antagonist to accelerate upper and lower gastrointestinal recovery. The company also develops Tedizolid Phosphate, a novel antibiotic product candidate for the treatmen...
65 Hayden Avenue
Lexington, MA 02421
Founded in 1992
Key Executives for Cubist Pharmaceuticals LLC
Chief Operating Officer and Executive Vice President
Chief Compliance Officer and Senior Vice President of Global Compliance & Risk
Senior Vice President of Scientific Affairs
Senior Vice President of Discovery and Pharmaceutical Sciences
Chief Intellectual Property Counsel, Head of Litigation and Vice President
Compensation as of Fiscal Year 2016.
Cubist Pharmaceuticals LLC Key Developments
Cubist Pharmaceuticals Presents at Leerink Healthcare Summit, Sep-22-2016 10:30 AM
Sep 19 16
Cubist Pharmaceuticals Presents at Leerink Healthcare Summit, Sep-22-2016 10:30 AM. Venue: Napa Valley, California, United States. Speakers: Mike Bonney, Former CEO.
Cubist Pharmaceuticals Inc. Presents at Boston CEO Conference, May-26-2015 through May-27-2015
Apr 16 15
Cubist Pharmaceuticals Inc. Presents at Boston CEO Conference, May-26-2015 through May-27-2015. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Presentation Date & Speakers: May-26-2015, Rob Perez. May-27-2015, Rob Perez.
Cubist Pharmaceuticals Files Form 15
Feb 2 15
Cubist Pharmaceuticals, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock, $0.001 par value under the Securities Exchange Act of 1934, as amended.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries